Fig. 3

The stacked column chart illustrates the percentage of developing embryos with isolated neural tube defect (INTD) and multiple neural tube defects at 120 hpf in embryos exposed to different concentrations of decitabine (DCT) (n=20). The phenotypic outcomes with isolated neural tube defects (INTDs) noted in groups exposed to decitabine 250 µM, 500 µM, 750 µM and 1 mM was 5%, 15%, 10% and 5% respectively. The phenotypic outcomes with multiple neural tube defects (MNTDs) in groups exposed to decitabine 250 µM, 500 µM, 750 µM and 1mM was 5%, 50%, 75% and 95% respectively. A concentration dependent increase in severity of neural tube defect was noted in groups exposed to decitabine. With 95% of developing embryos suffering from multiple neural tube defects and 5% from isolated neural tube defects, all of the embryos in the group exposed to 1 mM decitabine had neural tube defects